AzTrials
AzTrials

MyopiaNCT01216475

Randomized, Non-inferiority Trial Comparing SMILE and LASIK

A study testing Femtosecond LASIK and Small incision lenticule extraction (SMILE) in people with Myopia and Astigmatism, run by Singapore National Eye Centre at 1 site in Singapore.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background: Small Incision Lenticule Extraction or SMILE is a novel form of 'flapless' corneal refractive surgery that was adapted from Refractive Lenticule Extraction (ReLEx). SMILE uses only one femtosecond laser to complete the refractive surgery, potentially reducing surgical time, side effects and cost. Read more about this study

Who is it for?
Ages 21 years and olderHealthy volunteers can take part
Conditions the study is for
Myopia, Astigmatism, Hypermetropia
What is being tested?
Femtosecond LASIK and Small incision lenticule extraction (SMILE)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteSingapore
Study dates
Feb 2012to Sep 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 21 years of age or older.
  • Cycloplegic spherical equivalent of >-2.00D
  • Refractive cylinder -4.00 D or less, Anisometropia of >1D
  • Best spectacle corrected visual acuity (BSCVA) of 6/12 or better in BOTH eyes.
  • Spherical or cylindrical error has progressed at -0.50D or less per year from date of baseline measurement.
  • Contact lens wearers must have removed contact lenses at least two (2) weeks before the baseline measurement.
  • No evidence of irregular astigmatism on corneal topography.
  • Available to attend post-operative examinations for a 3 month period.

Who cannot join

  • Progressive or unstable myopia and/or astigmatism.
  • Clinical or corneal topographic evidence of keratoconus.
  • Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract and retinal disease.
  • Previous corneal surgery or trauma within the corneal flap zone.
  • Patent corneal vascularization within 1mm of the corneal flap zone.
  • Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites.
Show all 9Show fewer
  • Systemically immunocompromised.
  • Systemic disease likely to affect wound healing, such as diabetes, connective tissue disease and severe atopy.
  • Pregnant or nursing.

Trial locations and contacts

1 site in 1 country.

Donald T Tan, FRCS(Ed), contact

6562263395

snecdt@pacific.net.sg

Jodhbir S Mehta, FRCS(Ed) contact

65622772565

jodmehta@gmail.com

Singapore1 site, 1 recruiting
  • Singapore National Eye Centre

    Singapore, Singapore, 168751

    Jod Mehta, FRCOph, 62277255, jodmehta@gmail.com

    Donald T Tan, FRCS (Ed)

    Recruiting

Other trials in Singapore

About this study

Official title: Comparison of Small Incision Lenticule Extraction (SMILE) and VisuMax Femtosecond Laser In Situ Keratomileusis (FemtoLASIK): A Randomized, Non-inferiority Trial

Background: Small Incision Lenticule Extraction or SMILE is a novel form of 'flapless' corneal refractive surgery that was adapted from Refractive Lenticule Extraction (ReLEx). SMILE uses only one femtosecond laser to complete the refractive surgery, potentially reducing surgical time, side effects and cost. If successful, SMILE could potentially replace the current, widely practiced Laser In-situ Keratomileusis or LASIK. The aim of this study is to evaluate whether SMILE is non-inferior to LASIK in terms of refractive outcomes at 3-months post-operatively.

Methods/ Design: Single tertiary center, parallel group, single-blinded, paired-eye design, non-inferiority, randomized controlled trial. Participants who are eligible for LASIK will be enrolled for study after informed consent. Each participant will be randomized to receive SMILE and LASIK in each eye. Our primary hypothesis (stated as null) in this non-inferiority trial would be that SMILE differs from LASIK in adults (>21 years old) with myopia (> -3.00D) at a tertiary eye center in terms of refractive predictability at 3 months post-operatively. Our secondary hypothesis (stated as null) in this non-inferiority trial would be that SMILE differs from LASIK in adults (>21 years old) with myopia (> -3.00D) at a tertiary eye center in terms of other refractive outcomes (efficacy, safety, higher-order aberrations) at 3 months post-operatively. Our primary outcome is refractive predictability, which is one of several standard refractive outcomes, defined as the proportion of eyes achieving a postoperative spherical equivalent (SE) within ±0.50 diopter (D) of the intended target. Randomization will be performed using random allocation sequence generated by a computer with no blocks or restrictions, and implemented by concealing the number-coded surgery within sealed envelopes until just before the procedure. In this single-blinded trial, subjects and their caregivers will be blinded to the assigned treatment in each eye.

Discussion: This novel trial will provide information on whether SMILE has comparable, if not superior, refractive outcomes compared to the established LASIK for myopia, thus providing evidence for translation into clinical practice.

Read the detailed description

Surgical correction for refractive errors may be performed by a number of procedures. Laser correction involves procedures such as EpiLASIK, LASIK or conductive keratoplasty, while lens based corrections involve the use of phakic intra-ocular lenses. Despite the emergence of other procedures, due to its fast visual rehabilitation and painless postoperative course, LASIK is still the procedure of choice for both patients and refractive surgeons.

LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma. The advantages of femtosecond laser over microkeratome LASIK flaps have been reduced postoperative dry eye symptoms, less chance of dislocation from trauma and reduced incidence of button holes or free caps.

Even though femto-LASIK has demonstrated good efficacy, it can still be asssociated with side effects found in standard LASIK e.g. glare, haloes, dry eye and still requires the use of two laser machines, one for the flap the other for the excimer ablation. This increases the length of time of the overall procedure and the costs.

Recently, a new "one laser" refractive surgery has been proposed: Femtosecond Lenticule Ex-traction (FLEx). It consists of performing the entire refractive procedure without an excimer laser. The Femtosecond laser creates four stromal incisions to create a corneal lenticule and a corneal flap. The size and shape of the lenticule is calculated based on the patient refractive error. The lenticule is separated from the flap above and the rest of the cornea below using a small spatula. Following this, the lenticule is grasped with a forceps and extracted from the eye. Finally, the flap is repositioned and the interface washed. At this time the refractive error is already corrected without the use of a second laser.

The advantages of FLEx treatment are shortened length of the refractive procedure, reduced patient inconvenience from moving from one laser to another, reduced risk of intraoperative infections and more accurate ablation since the patient need to fixate only once.

Currently there are no publications comparing FLEx to LASIK, hence this study will be unique in the fact that the paired eye approach will act as an internal patient control to assess the objective and subjective outcomes in patients following both these procedures.

The study will be a prospective randomized trial of patients comparing SMILE (a variation of FLEx) with LASIK to treat their myopic refractive error. One eye will be randomized for SMILE and other eye for LASIK. Each procedure will be performed sequentially. Randomization will be performed by a random number generator, and assignment concealed in envelopes.

Being tested
Femtosecond LASIK, Small incision lenticule extraction (SMILE)
Medical subject headings
Myopia, Astigmatism, Hyperopia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Femtosecond LASIKProcedure or surgery

    Also called Blade-less LASIK

    LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.

  • Small incision lenticule extraction (SMILE)Procedure or surgery

    Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.

Study groups in NCT01216475
Study groupRoleWhat they receive
Femtosecond LASIKActive comparator2 lasers refractive procedure
Receives: Procedure: Femtosecond LASIK
SMILEExperimentalSmall incision lenticule extraction (SMILE)
Receives: Procedure: Small incision lenticule extraction (SMILE)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Refractive predictability

    Defined as the proportion number of eyes achieving a postoperative spherical equivalent (SE) within ±0.50 diopter (D) of the intended target.

    Measured: 3 months Post-operative

Secondary outcomes (3)
  1. Efficacy

    Defined as the proportion number of eyes achieving a unaided visual acuity (UAVA) of 20/20 or better postoperatively

    Measured: 3 months Post-operative

  2. Safety

    Defined as the proportion number of eyes that lost or gained 1 or more lines of postoperative best-corrected visual acuity (BCVA) relative to the preoperative BCVA

    Measured: 3 months Post-operative

  3. Contrast sensitivity

    Tested using the Vision Contrast Test System (VCTS) chart (VCTS 6500 contrast sensitivity Chart) in 6 spatial frequencies

    Measured: 3 months Post-operative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Oct 2010 (estimated)
  2. Study startFeb 2012
  3. Primary completionNov 2016 (estimated)
  4. Study completionSep 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01216475
Sponsor's protocol ID
R788/72/2010
Status last verified
Jul 2016
First submitted
8 Sep 2010
Last updated
20 Jul 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Sekundo W, Kunert K, Russmann C, Gille A, Bissmann W, Stobrawa G, Sticker M, Bischoff M, Blum M. First efficacy and safety study of femtosecond lenticule extraction for the correction of myopia: six-month results. J Cataract Refract Surg. 2008 Sep;34(9):1513-20. doi: 10.1016/j.jcrs.2008.05.033.

    PubMed 18721712
  • Ang M, Tan D, Mehta JS. Small incision lenticule extraction (SMILE) versus laser in-situ keratomileusis (LASIK): study protocol for a randomized, non-inferiority trial. Trials. 2012 May 31;13:75. doi: 10.1186/1745-6215-13-75.

    PubMed 22647480

Questions about this trial

What is this clinical trial studying?

A study testing Femtosecond LASIK and Small incision lenticule extraction (SMILE) in people with Myopia and Astigmatism, run by Singapore National Eye Centre at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Donald T Tan, FRCS(Ed), (6562263395, snecdt@pacific.net.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Refractive predictability (time frame: 3 months Post-operative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01216475, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in